



Review Article



Phytosomes: A Promising Nanocarrier for Enhanced Delivery of Herbal Compounds in Cancer Therapy

Muhammad Saeed^{1,*} , Soheil Sadr² , Arian Gharib³ , Narges Lotfalizadeh² , Ashkan Hajjafari⁴ , Pouria Ahmadi Simab³ , and Hassan Borji⁵

¹ Institute of Animal Sciences, Faculty of Animal Husbandry, University of Agriculture, Faisalabad, 38040, Pakistan

² Department of Clinical Sciences, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran

³ Department of Clinical Sciences, Faculty of Veterinary Medicine, Sanandaj Branch, Islamic Azad University, Sanandaj, Iran

⁴ Department of Pathobiology, Faculty of Veterinary Medicine, Islamic Azad University, Science and Research Branch, Tehran, Iran

⁵ Department of Pathobiology, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran

* **Corresponding author:** Muhammad Saeed, Institute of Animal Sciences, Faculty of Animal Husbandry, University of Agriculture, Faisalabad, 38040, Pakistan.
Email: msaeed@cuvas.edu.pk

ARTICLE INFO

Article History:

Received: 17/10/2022

Accepted: 26/11/2022

Keywords:

Herbal medicine

Osteoporosis

Postmenopausal osteoporosis

ABSTRACT

Cancer is a life-threatening disease that remains a global health problem, with millions of people diagnosed yearly. Despite significant progress in cancer treatment, conventional chemotherapy still faces several limitations, including poor solubility, low bioavailability, lack of selectivity, and severe side effects. Therefore, alternative therapeutic strategies are necessary to improve cancer therapy. This review aimed to provide an updated overview of phytosome complexes and their potential application in cancer therapy, including their formulation techniques, transportation mechanism through phytosome, and recent investigations on their efficacy in treating different types of cancers. In recent years, nanotechnology has emerged as a promising approach to cancer therapy, as it enables the delivery of therapeutic agents to the tumor site with higher selectivity and efficiency. Phytosomes are a nanotechnology-based drug delivery system conjugating plant extracts or phytoconstituents with phospholipids. This conjugation results in the formation of a complex with improved solubility, stability, and bioavailability. Phytosomes have been shown to enhance the pharmacokinetic profile of phytoactive compounds, allowing for better targeting and sustained release. Phytosomes of curcumin, resveratrol, and quercetin have demonstrated anticancer properties in various *in vitro* and *in vivo* models. Moreover, phytosomes have been used to deliver chemotherapeutic agents, such as paclitaxel, docetaxel, and camptothecin, with improved efficacy and reduced toxicity. Phytosome complexes offer a promising platform for cancer therapy due to their ability to enhance the bioavailability and efficacy of phytoactive compounds. Incorporating phytosomes in cancer therapy could lead to the development of more effective and less toxic treatments for different types of cancers. Further studies are needed to elucidate the mechanism of action of phytosomes and to optimize their formulation for clinical use.

1. Introduction

Cancer is a complex disease that results from the uncontrolled growth and proliferation of cells¹. It is a leading cause of death worldwide, and its incidence is expected to rise in the coming years. Despite significant progress in cancer treatment, chemotherapy remains limited due to poor solubility, low bioavailability, and systemic toxicity². Therefore, there is a need to develop

novel drug delivery systems that can overcome these limitations and improve cancer therapy. Nanotechnology-based drug delivery systems have emerged as promising platforms for improving cancer therapy³. These systems utilize various nanostructures, such as liposomes, micelles, dendrimers, and nanoparticles, to deliver anticancer agents to the site of action^{4,5}. Among them, lipid-based

nanocarriers have received significant attention due to their biocompatibility, low toxicity, and ease of preparation⁶. These nanocarriers include liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and phytosomes⁷.

Phytosomes are lipid-based nanocarriers that conjugate plant extracts or phytoconstituents with phospholipids⁸. This conjugation results in the formation of a complex with improved solubility, stability, and bioavailability⁹. Several studies have reported the potential of phytosomes in cancer therapy¹⁰. For instance, phytosomes of curcumin, resveratrol, and quercetin have shown anticancer properties in various *in vitro* and *in vivo* models¹¹. Moreover, phytosomes have been used to deliver chemotherapeutic agents, such as Paclitaxel, Docetaxel, and Camptothecin, with improved efficacy and reduced toxicity^{12,13}. Phytosomes can be prepared using various techniques, including solvent evaporation, thin-film hydration, and coacervation¹⁴. Solvent evaporation involves dissolving the phytoconstituent and phospholipid in a common solvent and evaporating the solvent to form a thin film¹⁵. Thin-film hydration hydrates the thin film with an aqueous phase to form liposomes. Coacervation involves mixing the phytoconstituent and phospholipid in a non-aqueous solvent and then adding water to create phytosomes¹⁶. These techniques can be modified to achieve different properties, such as size, drug loading capacity, and stability¹⁷. Phytosomes are characterized by their stability, size, and drug-loading capacity. The stability of phytosomes is due to the formation of chemical links between phospholipid molecules and phytoactive agents. The size of phytosomes ranges from 50-200 nm, which allows them to bypass the reticuloendothelial system and accumulate at the tumor site through the enhanced permeability and retention effect¹⁸. The drug-loading capacity of phytosomes depends on the solubility of the phytoconstituent and the type of phospholipid used.

2. Advantages of phytosomes

Phytosomes are a promising delivery system for phytoactive compounds, as they offer several advantages over other delivery systems. One of the main advantages is their simple production method compared to other nano delivery systems, such as NLC and SLN. This ease of production makes phytosomes a cost-effective option for drug delivery¹⁹.

Another major advantage of phytosomes is their ability to improve the oral absorption of polar phytoactive compounds, leading to better bioavailability and greater therapeutic effects²⁰. This is due to the ability of the phospholipid molecules in the phytosome to form chemical links with the phytoactive compounds, increasing their stability and solubility in aqueous solutions.

In addition, phytosomes have been found to significantly increase drug/nutraceutical entrapment, allowing for a more targeted and efficient delivery of the active compound to the site of action²¹. The enhanced cellular uptake of phytoactive constituents further reduces

the required dose, minimizing potential side effects and toxicity.

Furthermore, the use of phosphatidylcholine in phytosomes provides hepatoprotective and synergistic effects when combined with other hepatoprotective constituents²²⁻²⁴. This dual effect can be beneficial in the treatment of liver diseases.

Phytosomal formulations have also shown potential in enhancing percutaneous absorption of phytoconstituents, making them a viable option for topical applications in treating skin conditions²⁵.

Finally, phospholipids in phytosomes offer a dual nutritional benefit, as they not only enhance the delivery of phytoactive compounds but also provide essential nutrients for cellular membrane function and overall health²⁶.

In summary, the advantages of phytosomes make them an attractive option for delivering phytoactive compounds, offering enhanced cellular uptake, improved bioavailability, and reduced required doses, among other benefits. Further research and development in this area can potentially revolutionize cancer therapy and other areas of medicine.

3. Phytosome in cancer therapy

Nanophytosomes have emerged as a promising drug delivery system for improving the bioavailability and efficacy of plant-derived anticancer compounds. These lipid-based nanocarriers offer several advantages over traditional delivery systems, such as improved cellular uptake, increased bioavailability, and reduced toxicity. Recent studies have explored the potential of nanophytosomes in cancer therapy, demonstrating their efficacy in delivering phytoconstituents to cancer cells with minimal cytotoxic effects on normal cells.

3.1. Silibinin phytosome

Silibinin is a natural flavonolignan compound extracted from milk thistle (*Silybum marianum*) and used as a traditional medicine for liver diseases²⁷. In recent years, *Silibinin* has gained considerable attention due to its potent anticancer activities against various cancer cells, including hepatocellular carcinoma, prostate cancer, breast cancer, and lung cancer²⁸⁻³⁰.

Several mechanisms have been proposed to explain the anticancer effects of *Silibinin*. One of the major mechanisms is the inhibition of cancer cell proliferation through the induction of cell cycle arrest and apoptosis. *Silibinin* has also been shown to inhibit angiogenesis, invasion, and metastasis of cancer cells by targeting various signaling pathways, such as NF- κ B, Wnt/ β -catenin, PI3K/Akt, and MAPK³¹.

However, one of the major challenges in using *Silibinin* as a therapeutic agent is its poor bioavailability, which limits its clinical efficacy. To overcome this limitation, various drug delivery systems, including nanoparticles, liposomes, and phytosomes, have been developed to

improve the solubility, stability, and targeting of *Silibinin*^{32,33}.

Phytosomes are a novel drug delivery system that involves complexing a drug with phospholipids to form a lipid bilayer structure. This structure improves the bioavailability of the drug by increasing its absorption and reducing its metabolism and elimination. Ochi et al. 2016 demonstrated the potential of phytosomes in improving the therapeutic effects of *Silibinin* by co-encapsulating it with glycyrrhizic acid, another anticancer compound, in nanophytosomes³⁴. The results showed that the co-encapsulated nanophytosomes were more potent than individual *Silibinin* and glycyrrhizic acid in inhibiting the proliferation of hepatocellular carcinoma cell lines.

Similarly, Lazzeroni et al. 2016 investigated using Silybin nanophytosomes (SNPs) as a delivery system for treating early breast cancer patients³⁵. The results showed that the SNPs significantly increased the plasma levels of Silybin and its accumulation in the tumor tissue, which led to a significant reduction in tumor size and improved clinical outcomes. This study demonstrated the potential of nanophytosomes in overcoming poor bioavailability of Silybin and improving its therapeutic efficacy.

In conclusion, *Silibinin* has shown promising anticancer activities against various cancer cells, but its poor bioavailability remains a major challenge in its clinical application. Nanophytosomes, as a novel drug delivery system, have shown great potential in improving the bioavailability and therapeutic efficacy of *Silibinin* by improving its absorption, stability, and targeting. Further studies are needed to optimize the formulation and dosage of nanophytosomes and to evaluate their safety and efficacy in clinical trials.

3.2. *Sinigrin* phytosome

Cancer is a major public health concern worldwide, and skin cancer is one of the most prevalent types of cancer³⁶. Using wound healing agents with concomitant cytotoxic effects against cancer cells is an attractive approach to treating skin cancers. *Sinigrin*, a natural compound found in the Brassicaceae family, has been shown to have antitumor activities. In an innovative study, Mazumder et al. investigated the wound-healing effects of *Sinigrin* on normal human keratinocyte cells (HaCaT) and the anticancer effects of its phytosomal formulation on A-375 melanoma cells³⁷. The study revealed that *Sinigrin*-loaded phytosomes had significant superiority over free *Sinigrin* in cytotoxicity against A-375 cell lines. Moreover, minimal cytotoxic effects were observed on normal cells (HaCaT). The *in vitro* wound healing investigation on HaCaT cells showed 50% more wound closure at various concentrations and times. These results suggest that *Sinigrin*-loaded phytosomes may be a promising candidate for cancer therapy and cancerous wound treatment³⁸.

Phytosomes are a novel delivery system that has been shown to improve the bioavailability of natural compounds, including anticancer agents. Phytosomes are lipid-based nanoparticles containing a natural compound, such as

Sinigrin, encapsulated within a phospholipid bilayer³⁹. This encapsulation increases the solubility and stability of the compound, thereby enhancing its bioavailability.

Using *Sinigrin*-loaded phytosomes as a therapeutic agent is a novel approach to treating skin cancers. *Sinigrin* has been shown to have antitumor effects by inducing apoptosis and inhibiting cell proliferation. The phytosomal formulation of *Sinigrin* may allow for more efficient delivery of the compound to cancer cells while minimizing its effects on normal cells⁴⁰.

In conclusion, using *Sinigrin*-loaded phytosomes as a delivery system for treating skin cancers has great potential. Combining wound healing and the anticancer effects of *Sinigrin*-loaded phytosomes may lead to more effective treatments with a fewer side effects. Further studies are warranted to fully explore the potential of *Sinigrin*-loaded phytosomes as a novel cancer therapy.

3.3. *Mitomycin* phytosome

In addition to its potent antitumor activities, Mitomycin C (MMC) has also shown promising results in treating a wide range of cancers⁴¹⁻⁴³. However, the rapid absorption of MMC into systemic circulation has been a major obstacle in its clinical application. This leads to a decrease in the plasma concentration of the drug in the relevant sites, resulting in a decrease in therapeutic efficacy.

Researchers have developed various drug delivery systems for MMC to overcome this limitation. One such innovative approach was developed by Hou et al., who developed a delivery system of MMC-soybean loaded phytosomes PC (MMC-SPC) complex with a mean particle size of 210nm⁴⁴. The phytosome complex comprises a phospholipid bilayer shell that encapsulates the MMC and protects it from rapid absorption into systemic circulation.

In vitro release studies showed that the MMC release from the phytosome complex was sustained after its first burst release, indicating that the phytosomes effectively protected MMC from rapid absorption into systemic circulation⁴⁵. Using phytosomes also increases the lipophilicity of MMC, further enhancing its ability to penetrate cancer cells.

In vivo studies on H22 solid tumor-bearing model mice showed that the tumor inhibition rate of the phytosomes loaded with MMC was six times more than that of MMC injection⁴⁴. This indicates that the phytosome complex significantly improved the therapeutic efficacy of MMC.

The development of MMC-loaded phytosomes as a drug delivery system represents a novel approach to cancer therapy. The use of phytosomes provides a means to protect MMC from rapid absorption into systemic circulation and to enhance its therapeutic efficacy against cancer cells. Further studies in this area may lead to the development of more effective and targeted cancer therapies.

3.4. *Curcumin* phytosome

Curcuma longa, commonly known as turmeric, is an

ancient traditional herb used for its medicinal properties for centuries⁴⁶. It contains natural hydrophobic polyphenols and chemical compounds called curcuminoids, which have been shown to have comprehensive pharmacological activities, including beneficial effects on treating different types of cancers⁴⁷. However, curcumin therapeutic is often hindered by its poor solubility and bioavailability in oral administration. This has led to the design of several formulation methods and other approaches to combat those obstacles and facilitate its clinical application⁴⁸.

One such approach is using delivery systems to enhance the solubility and bioavailability of curcumin. In a comparative study conducted by Purpura et al. 2018, the plasma levels of curcuminoids with different delivery systems, including curcumin-gamma-cyclodextrin (CW8), curcumin phytosome (CSL), and standard plain curcumin (STDC), were investigated via oral administration⁴⁹. The plasma measurement for demethoxycurcumin showed a similar plasma level for CSL and CW8 delivery systems, significantly more than STDC. For bisdemethoxycurcumin, the CSL plasma level was significantly more than CW8. However, for curcumin, the plasma level reported the supremacy of CW8 to CSL. Although in this study, curcumin plasma level for CW8 was reported to be more than for CSL, both delivery systems showed significantly more plasma levels than plain curcumin.

In addition to delivery systems, other approaches to enhance the therapeutic efficacy of curcumin have also

been explored. For instance, curcumin-based nanoparticles have been developed to increase the bioavailability and targetability of curcumin in cancer cells. In a recent study by Rashidzadeh et al. 2019, curcumin-loaded nanostructured lipid carriers (NLCs) were developed and evaluated for their potential in breast cancer therapy⁵⁰. The results showed that the curcumin-NLCs exhibited higher cellular uptake and cytotoxicity in breast cancer cells, compared to free curcumin. Moreover, the curcumin-NLCs showed improved tumor accumulation and therapeutic efficacy in a mouse model of breast cancer.

Furthermore, curcumin has been combined with other natural compounds to enhance its therapeutic efficacy. In a study by Khanna et al., a combination of curcumin and piperine, a natural alkaloid found in black pepper, was evaluated for its therapeutic potential in treating multiple myeloma⁵¹. The results showed that the curcumin-piperine combination exhibited a significant inhibitory effect on multiple myeloma cells compared to curcumin alone.

In conclusion, curcumin is a promising natural chemical agent with beneficial effects on treating different types of cancers. However, its poor solubility and bioavailability in oral administration often limit its therapeutic efficacy. Therefore, various approaches, including delivery systems, nanoparticles, and combination therapy, have been explored to overcome these limitations and enhance the therapeutic efficacy of curcumin. These novel approaches hold great promise for the future development of curcumin-based cancer therapies (Figure 1).




Figure 1. Current status of phytosomes

4. Challenges and future

While the potential of phytosome technology for cancer therapy is promising, there have been limited investigations on using phytosomes as a carrier for anticancer agents. Despite this, a few products have emerged on the market, such as Meriva® (curcumin phytosomes) and Siliphos® (Silybin phytosomes)⁵². One major challenge facing the industrial production of phytosomes is the pH sensitivity of their structures, which can impact their physicochemical stability⁵³. This challenge must be addressed for the industrial-scale production of these nanocarriers to be feasible in the future.

One interesting aspect of phytosomes is that they can be produced using food-grade procedures, which can remove the potential side effects associated with non-food-grade production methods. This is important for ensuring that the phytosomes are safe for cancer therapy. Flavonoids and other herbal medicines have recently gained much attention in cancer therapy, but their poor oral bioavailability has limited their clinical applications⁵⁴. Lipid-based nanoparticles, such as phytosomes, offer many advantages over other drug carriers due to their biocompatibility, biodegradability, low cost, and abundant availability of raw materials⁵⁵.

Phytosomes can be used as effective carriers for drug delivery because their cores consist of phospholipids and cholesterol, similar to biomembranes⁵⁶. These lipids are readily accepted by the human body without causing antigenic or pyrogenic responses, making them a promising option for cancer therapy. Phytosomes are also biologically neutral and induce low immunogenic reactions⁵⁷.

However, some challenges are still associated with using phytosomes for drug delivery. One concern is their ability to merge with bilayer phospholipid biological membranes, which could result in non-specific drug delivery to healthy tissues⁵⁸. To address this issue, new approaches for active targetings, such as antibody- or peptide-targeted delivery, must be developed and applied to increase the anticancer efficiency of phytosomes while reducing their toxicity to normal tissues⁵⁹.

Despite the challenges associated with the formulation of nanophytosomes, this concept and technology hold great promise for cancer therapy. Recent developments in industrial-scale production of vesicular systems, including extruding methods, offer optimistic horizons for the commercial fabrication of these systems. While the high cost of raw materials, such as pegylated soy phosphatidylcholine may pose a challenge, the formulating herbal and synthetic anticancer agents into nanophytosomes has already been shown to increase oral bioavailability and reduce tumor growth⁶⁰. Future studies assessing the efficacy and toxicity of nanophytosomes in large animal models and Phase I/II clinical trials will be necessary to explore their potential for cancer therapy fully.

5. Conclusion

The efficacy of botanical preparations is mainly

attributed to their health-promoting compounds, including flavonoids and other phenolic compounds. Hence, it is essential to employ appropriate delivery mechanisms to deliver sufficient quantities of active ingredients to the body. Phytosomes represent a novel drug delivery system that enhances the bioavailability of phytoconstituents and other natural plant-based compounds through the gastrointestinal tract. The advantages of phytosomes over other conventional nano-delivery carriers are undeniable. Formulating phytosomes is facile and can be easily scaled up for commercial production. Additionally, the preparation, characterization, and analytical techniques for this delivery system are well-established. Phytosomes demonstrate excellent potential as a nano-formulation technique for nutraceuticals, and they could serve as a promising candidate for delivering hydrophilic plant compounds for cancer therapy.

Declarations

Competing interests

The authors have declared no conflicts of interest.

Authors' contributions

The study was conceptualized by Muhammad Saeed, with all authors participating in the development of the methodology. Formal analysis and investigation of the research were carried out by all authors, and the writing process, including the preparation of the original draft and subsequent review and editing, was a collaborative effort. Muhammad Saeed provided supervision for the project, and all authors thoroughly reviewed and approved the final version of the manuscript before submitting it for publication in the present journal.

Funding

No funding was received for conducting this study.

Ethical considerations

The authors declare that this manuscript is original and has not been submitted elsewhere for possible publication. The authors also declare that the data used/presented in this manuscript has not been fabricated.

Availability of data and materials

The authors will provide data from the present study in case of request.

Acknowledgments

None.

References

1. Tzenios N. A new hallmark of cancer: Stemness. Special J Med Acad

- Sci. 2023; 1(1). DOI: [10.58676/sjmas.v1i1.3](https://doi.org/10.58676/sjmas.v1i1.3)
2. Cheng Z, Li M, Dey R, and Chen Y. Nanomaterials for cancer therapy: Current progress and perspectives. *J of Hematol oncolo*. 2021; 14(1): 1-27. DOI: [10.1186/s13045-021-01096-0](https://doi.org/10.1186/s13045-021-01096-0)
3. Hani U, Osmani RAM, Yasmin S, Gowda BJ, Ather H, and Ansari MY, et al. Novel drug delivery systems as an emerging platform for stomach cancer therapy. *Pharmaceutics*. 2022; 14(8): 1576. DOI: [10.3390/pharmaceutics14081576](https://doi.org/10.3390/pharmaceutics14081576)
4. Sahu T, Ratre YK, Chauhan S, Bhaskar L, Nair MP, and Verma HK. Nanotechnology based drug delivery system: Current strategies and emerging therapeutic potential for medical science. *J Drug Deliv Sci Technol*. 2021; 63: 102487. DOI: [10.1016/j.jddst.2021.102487](https://doi.org/10.1016/j.jddst.2021.102487)
5. Chivere VT, Kondiah PP, Choonara YE, and Pillay V. Nanotechnology-based biopolymeric oral delivery platforms for advanced cancer treatment. *Cancer*. 2020; 12(2): 522. DOI: [10.3390/cancers12020522](https://doi.org/10.3390/cancers12020522)
6. Waghule T, Gorantla S, Rapalli VK, Shah P, Dubey SK, Saha RN, et al. Emerging trends in topical delivery of curcumin through lipid nanocarriers: Effectiveness in skin disorders. *AAPS Pharm Sci Tech*. 2020; 21: 284. DOI: [10.1208/s12249-020-01831-9](https://doi.org/10.1208/s12249-020-01831-9)
7. Lu H, Zhang S, Wang J, and Chen Q. A review on polymer and lipid-based nanocarriers and its application to nano-pharmaceutical and food-based systems. *Front Nutr*. 2021; 8: 783831. DOI: [10.3389/fnut.2021.783831](https://doi.org/10.3389/fnut.2021.783831)
8. Alharbi WS, Almughem FA, Almeahmady AM, Jarallah SJ, Alsharif WK, Alzahrani NM, et al. Phytosomes as an emerging nanotechnology platform for the topical delivery of bioactive phytochemicals. *Pharmaceutics*. 2021; 13(9): 1475. DOI: [10.3390/pharmaceutics13091475](https://doi.org/10.3390/pharmaceutics13091475)
9. Pal P, Dave V, Paliwal S, Sharma M, Potdar MB, and Tyagi A. Phytosomes-nanoarchitectures' promising clinical applications and therapeutics. *Nanopharm Adv Deliv Syst*. 2021. p. 187-216. DOI: [10.1002/9781119711698.ch9](https://doi.org/10.1002/9781119711698.ch9)
10. Babazadeh A, Zeinali M, and Hamishehkar H. Nano-phytosome: A developing platform for herbal anticancer agents in cancer therapy. *Curr drug target*. 2018; 19(2): 170-180. DOI: [10.2174/1389450118666170508095250](https://doi.org/10.2174/1389450118666170508095250)
11. Patra S, Pradhan B, Nayak R, Behera C, Rout L, Jena M, et al. Chemotherapeutic efficacy of curcumin and resveratrol against cancer: Chemoprevention, chemoprotection, drug synergism and clinical pharmacokinetics. *Semin Cancer Biol*; 2021; 73: 310-320. DOI: [10.1016/j.semcancer.2020.10.010](https://doi.org/10.1016/j.semcancer.2020.10.010)
12. Wani K, Tarawadi K, and Kaul-Ghanekar R. Nanocarriers for delivery of herbal based drugs in breast cancer-an overview. *J Nano Res*. 2015; 34: 29-40. DOI: [10.4028/www.scientific.net/JNanoR.34.29](https://doi.org/10.4028/www.scientific.net/JNanoR.34.29)
13. Kashyap D, Tuli HS, Yerer MB, Sharma A, Sak K, Srivastava S, et al. Natural product-based nanoformulations for cancer therapy: Opportunities and challenges. *Semin Cancer Biol*; 2021; 69: 5-23. DOI: [10.1016/j.semcancer.2019.08.014](https://doi.org/10.1016/j.semcancer.2019.08.014)
14. Sharma P, Verma S, and Misri P. Global need for novel herbal drug formulations. *Int J Pharmacog Phytochem Res*. 2016; 8: 1535-1544. Available at: <http://impactfactor.org/PDF/IJPPR/8/IJPPR,Vol8, Issue9,Article17.pdf>
15. Kaur G, Kaur P, Madaan P, Verma R, Chandel P, Salgotra T, et al. Herbal bioactives in transdermal drug delivery system. *Herb bioact-base drug deliv syst*. 2022. p. 93-110. DOI: [10.1016/B978-0-12-824385-5.00016-9](https://doi.org/10.1016/B978-0-12-824385-5.00016-9)
16. Pandey R, Bhairam M, Shukla SS, and Gidwani B. Colloidal and vesicular delivery system for herbal bioactive constituents. *DARU J Pharmaceu Sci*. 2021; 29(2): 415-438. DOI: [10.1007/s40199-021-00403-x](https://doi.org/10.1007/s40199-021-00403-x)
17. Das S, and Sharangi AB. Nanotechnology: A potential tool in exploring herbal benefits. In: Thangadurai D, Sangeetha J, Prasad R, editors. *Functional bionanomaterials: From biomolecules to nanoparticl*. 2020. p. 27-46. DOI: [10.1007/978-3-030-41464-1_2](https://doi.org/10.1007/978-3-030-41464-1_2)
18. Dubey SK, Dey A, Singhvi G, Pandey MM, Singh V, and Kesharwani P. Emerging trends of nanotechnology in advanced cosmetics. *Colloids Surf B Biointerfaces*. 2022; 214: 112440. DOI: [10.1016/j.colsurfb.2022.112440](https://doi.org/10.1016/j.colsurfb.2022.112440)
19. Pawar HA, and Bhangale BD. Phytosome as a novel biomedicine: A microencapsulated drug delivery system. *J Bioanal Biomed*. 2015; 7(1): 6-12. Available at: <https://www.hilarispublisher.com/open-access/phytosome-as-a-novel-biomedicine-a-microencapsulated-drug-delivery-system-1948-593X.1000116.pdf>
20. Kumar D, Vats N, Saroha K, and Rana AC. Phytosomes as emerging nanotechnology for herbal drug delivery. In: Saneja A, Panda A, Lichtfouse, E, editors. *Sustainable agriculture reviews* 43. 2020. p. 217-237. DOI: [10.1007/978-3-030-41838-0_7](https://doi.org/10.1007/978-3-030-41838-0_7)
21. Babazadeh A, Jafari SM, and Shi B. Encapsulation of food ingredients by nanophytosomes. *Lipid-based nanostructures for food encapsulation purposes*. 2019. p. 405-443. DOI: [10.1016/B978-0-12-815673-5.00010-6](https://doi.org/10.1016/B978-0-12-815673-5.00010-6)
22. Polachi N, Bai G, Li T, Chu Y, Wang X, Li S, et al. Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer-A comprehensive review. *Eur J Med Chem*. 2016; 123: 577-595. DOI: [10.1016/j.ejmech.2016.07.070](https://doi.org/10.1016/j.ejmech.2016.07.070)
23. Tung BT, Hai NT, and Son PK. Hepatoprotective effect of Phytosome Curcumin against paracetamol-induced liver toxicity in mice. *Braz J Pharm Sci*. 2017; 53(1): e16136. DOI: [10.1590/s2175-97902017000116136](https://doi.org/10.1590/s2175-97902017000116136)
24. Shriram RG, Moin A, Alotaibi HF, Khafagy ES, Al Saqr A, Abu Lila AS, et al. Phytosomes as a plausible nano-delivery system for enhanced oral bioavailability and improved hepatoprotective activity of silymarin. *Pharmaceutics*. 2022; 15(7): 790. DOI: [10.3390/ph15070790](https://doi.org/10.3390/ph15070790)
25. Tripathy S, Patel DK, Barob L, and Naira SK. A review on phytosomes, their characterization, advancement & potential for transdermal application. *J Drug Deliv Ther*. 2013; 3(3): 147-152. DOI: [10.22270/jddt.v3i3.508](https://doi.org/10.22270/jddt.v3i3.508)
26. Rathore P, and Swami G. Planterosomes: A potential phyto-phospholipid carriers for the bioavailability enhancement of herbal extracts. *Int J Pharmaceu Sci Res*. 2012; 3(3): 737-755. Available at: <https://ijpsr.com/bft-article/planterosomes-a-potential-phyto-phospholipid-carriers-for-the-bioavailability-enhancement-of-herbal-extracts/>
27. Abenavoli L, Izzo AA, Milić N, Cicala C, Santini A, and Capasso R. Milk thistle (*Silybum marianum*): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases. *Phytother Res*. 2018; 32(11): 2202-2213. DOI: [10.1002/ptr.6171](https://doi.org/10.1002/ptr.6171)
28. Davatgaran-Taghipour Y, Masoomzadeh S, Farzaei MH, Bahramsoltani R, Karimi-Soureh Z, Rahimi R, et al. Polyphenol nanoformulations for cancer therapy: Experimental evidence and clinical perspective. *Int J Nanomed*. 2017; 12: 2689-2702. DOI: [10.2147/IJN.S131973](https://doi.org/10.2147/IJN.S131973)
29. Tuli HS, Mittal S, Aggarwal D, Parashar G, Parashar NC, Upadhyay SK, et al. Path of Silibinin from diet to medicine: A dietary polyphenolic flavonoid having potential anticancer therapeutic significance. *Semin Cancer Biol*. 2021; 73: 196- 218. DOI: [10.1016/j.semcancer.2020.09.014](https://doi.org/10.1016/j.semcancer.2020.09.014)
30. Tyagi AK, Agarwal C, Chan DC, and Agarwal R. Synergistic anticancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells. *Oncol Rep*. 2004; 11(2): 493-499. DOI: [10.3892/or.11.2.493](https://doi.org/10.3892/or.11.2.493)
31. Singh B, Singh HB, Singh A, Naqvi AH, and Singh BR. Dietary phytochemicals alter epigenetic events and signaling pathways for inhibition of metastasis cascade: Phytoblockers of metastasis cascade. *Cancer and Metastasis Rev*. 2014; 33: 41-85. DOI: [10.1007/s10555-013-9457-1](https://doi.org/10.1007/s10555-013-9457-1)
32. Takke A, and Shende P. Nanotherapeutic silibinin: An insight of phytomedicine in healthcare reformation. *Nanomed: NBM*. 2019; 21: 102057. DOI: [10.1016/j.nano.2019.102057](https://doi.org/10.1016/j.nano.2019.102057)
33. Baishya R, Hati Boruah JL, Bordoloi MJ, Kumar D, and Kalita P. Novel drug delivery system in phytochemicals. In: Sen S, Chakraborty R, editors. *Herb Med India*. 2020. p. 175-189. DOI: [10.1007/978-981-13-7248-3_12](https://doi.org/10.1007/978-981-13-7248-3_12)
34. Ochi MM, Amoabediny G, Rezayat SM, Akbarzadeh A, and Ebrahimi B. *In vitro* co-delivery evaluation of novel pegylated nano-liposomal herbal drugs of silibinin and glycyrrhizic acid (nano-phytosome) to hepatocellular carcinoma cells. *Cell J*. 2016; 18(2): 135-148. Available at: <https://pubmed.ncbi.nlm.nih.gov/27540518/>
35. Lazzeroni M, Guerrieri-Gonzaga A, Gandini S, Johansson H, Serrano D, Cazzaniga M, et al. A presurgical study of oral silybin-phosphatidylcholine in patients with early breast cancer levels of silybin in breast cancer patients. *Cancer Prev Res*. 2016; 9(1): 89-95. DOI: [10.1158/1940-6207.CAPR-15-0123](https://doi.org/10.1158/1940-6207.CAPR-15-0123)
36. Jones OT, Ranmuthu CK, Hall PN, Funston G, and Walter FM. Recognising skin cancer in primary care. *Adv Ther*. 2020; 37: 603-616. DOI: [10.1007/s12325-019-01130-1](https://doi.org/10.1007/s12325-019-01130-1)
37. Mazumder A, Dwivedi A, Fox LT, Brümmer A, du Preez JL, Gerber M, et al. *In vitro* skin permeation of sinigrin from its phytosome complex. *J Pharm Pharmacol*. 2016; 68(12): 1577-1583. DOI: [10.1007/978-981-13-7248-3_12](https://doi.org/10.1007/978-981-13-7248-3_12)

- 10.1111/jphp.12594
38. Mazumder A, Dwivedi A, Du Preez JL, and Du Plessis J. *In vitro* wound healing and cytotoxic effects of sinigrin-phytosome complex. *Int J Pharmaceu.* 2016; 498(1-2): 283-293. DOI: [10.1016/j.ijpharm.2015.12.027](https://doi.org/10.1016/j.ijpharm.2015.12.027)
39. Barani M, Sangiovanni E, Angarano M, Rajizadeh MA, Mehrabani M, Piazza S, et al. Phytosomes as innovative delivery systems for phytochemicals: A comprehensive review of literature. *Int J Nanomed.* 2021; 16: 6983-7022. DOI: [10.2147/IJN.S318416](https://doi.org/10.2147/IJN.S318416)
40. Matias D, Rijo P, and Pinto Reis C. Phytosomes as biocompatible carriers of natural drugs. *Curr Med Chem.* 2017; 24(6): 568-589. DOI: [10.2174/0929867323666161028160855](https://doi.org/10.2174/0929867323666161028160855)
41. Xie L, Cheng L, and Wei Y. Mitomycin C enhanced the antitumor efficacy of Rocaglamide in colorectal cancer. *Pathol Res Prac.* 2023; 243: 154350. DOI: [10.1016/j.prp.2023.154350](https://doi.org/10.1016/j.prp.2023.154350)
42. Gabizon A, Shmeeda H, Tahover E, Kornev G, Patil Y, Amitay Y, et al. Development of promitil®, a lipidic prodrug of mitomycin c in PEGylated liposomes: From bench to bedside. *Adv drug deliv Rev.* 2020; 154: 13-26. DOI: [10.1016/j.addr.2020.07.027](https://doi.org/10.1016/j.addr.2020.07.027)
43. Wen T, Song L, and Hua S. Perspectives and controversies regarding the use of natural products for the treatment of lung cancer. *Cancer Med.* 2021; 10(7): 2396-422. DOI: [10.1002/cam4.3660](https://doi.org/10.1002/cam4.3660)
44. Hou Z, Li Y, Huang Y, Zhou C, Lin J, Wang Y, et al. Phytosomes loaded with mitomycin C-soybean phosphatidylcholine complex developed for drug delivery. *Mol Pharmaceu.* 2013; 10(1): 90-101. DOI: [10.1021/mp300489p](https://doi.org/10.1021/mp300489p)
45. Li Y, Wu H, Jia M, Cui F, Lin J, Yang X, et al. Therapeutic effect of folate-targeted and PEGylated phytosomes loaded with a mitomycin C-soybean phosphatidylcholine complex. *Mol Pharmaceu.* 2014; 11(9): 3017-3026. DOI: [10.1021/mp5001873](https://doi.org/10.1021/mp5001873)
46. Kocaadam B, and Şanlıer N. Curcumin, an active component of turmeric (*Curcuma longa*), and its effects on health. *Crit Rev Food Sci Nutr.* 2017; 57(13): 2889-2895. DOI: [10.1080/10408398.2015.1077195](https://doi.org/10.1080/10408398.2015.1077195)
47. Farnood PR, Pazhooh RD, Asemi Z, and Yousefi B. Targeting signaling pathway by curcumin in osteosarcoma. *Curr Mol Pharmacol.* 2023; 16(1): 71-82. DOI: [10.2174/1874467215666220408104341](https://doi.org/10.2174/1874467215666220408104341)
48. Hussain Y, Alam W, Ullah H, Dacrema M, Daglia M, Khan H, et al. antimicrobial potential of curcumin: Therapeutic potential and challenges to clinical applications. *Antibiotics.* 2022; 11(3): 322. DOI: [10.3390/antibiotics11030322](https://doi.org/10.3390/antibiotics11030322)
49. Purpura M, Lowery RP, Wilson JM, Mannan H, Münch G, Razmovski-and Naumovski V. Analysis of different innovative formulations of curcumin for improved relative oral bioavailability in human subjects. *Eur J Nut.* 2018; 57: 929-938. DOI: [10.1007/s00394-016-1376-9](https://doi.org/10.1007/s00394-016-1376-9)
50. Rashidzadeh H, Salimi M, Sadighian S, Rostamizadeh K, and Ramazani A. *In vivo* antiparasmodial activity of curcumin-loaded nanostructured lipid carriers. *Curr Drug Deliv.* 2019; 16(10): 923-930. DOI: [10.2174/1567201816666191029121036](https://doi.org/10.2174/1567201816666191029121036)
51. Khanna D, Sethi G, Ahn KS, Pandey MK, Kunnumakkara AB, Sung B, et al. Natural products as a gold mine for arthritis treatment. *Curr Opin Pharmacol.* 2007; 7(3): 344-351. DOI: [10.1016/j.coph.2007.03.002](https://doi.org/10.1016/j.coph.2007.03.002)
52. Khan J, Alexander A, Saraf S, and Saraf S. Recent advances and future prospects of phyto-phospholipid complexation technique for improving pharmacokinetic profile of plant actives. *J Control Release.* 2013; 168(1): 50-60. DOI: [10.1016/j.jconrel.2013.02.025](https://doi.org/10.1016/j.jconrel.2013.02.025)
53. Mishra DK, Shandilya R, and Mishra PK. Lipid based nanocarriers: A translational perspective. *Nanomedicine: NBM.* 2018; 14(7): 2023-2050. DOI: [10.1016/j.nano.2018.05.021](https://doi.org/10.1016/j.nano.2018.05.021)
54. Bonifacio BV, da Silva PB, Ramos MAdS, Negri KMS, Bauab TM, and Chorilli M. Nanotechnology-based drug delivery systems and herbal medicines: A review. *Int J Nanomed.* 2014; 1-15. DOI: [10.2147/IJN.S52634](https://doi.org/10.2147/IJN.S52634)
55. Bilia AR, Piazzini V, Guccione C, Risaliti L, Asprea M, Capecchi G, et al. Improving on nature: The role of nanomedicine in the development of clinical natural drugs. *Planta Medica.* 2017; 83(5): 366-381. DOI: [10.1055/s-0043-102949](https://doi.org/10.1055/s-0043-102949)
56. Rana M, Kumar A, and Rana AJ. Drug delivery through targeted approach with special references to phytosomes. In: Tyagi RK, Garg N, Shukla R, Bisen PS, editors. *Role of novel drug delivery vehicles nanobiomed.* 2020. p. 125. DOI: [10.5772/intechopen.86644](https://doi.org/10.5772/intechopen.86644)
57. Li J, Wang X, Zhang T, Wang C, Huang Z, Luo X, et al. A review on phospholipids and their main applications in drug delivery systems. *Asian J Pharmaceu Sci.* 2015; 10(2): 81-98. DOI: [10.1016/j.ajps.2014.09.004](https://doi.org/10.1016/j.ajps.2014.09.004)
58. Thanuja M, Anupama C, and Ranganath SH. Bioengineered cellular and cell membrane-derived vehicles for actively targeted drug delivery: So near and yet so far. *Adv Drug Deliv Rev.* 2018; 132: 57-80. DOI: [10.1016/j.addr.2018.06.012](https://doi.org/10.1016/j.addr.2018.06.012)
59. Allen TM, and Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. *Adv Drug Deliv Rev.* 2013; 65(1): 36-48. DOI: [10.1016/j.addr.2012.09.037](https://doi.org/10.1016/j.addr.2012.09.037)
60. Rasae S, Ghanbarzadeh S, Mohammadi M, and Hamishehkar H. Nano phytosomes of quercetin: A promising formulation for fortification of food products with antioxidants. *Pharmaceu Sci.* 2014; 20(3): 96-101. Available at: https://ps.tbzmed.ac.ir/Article/PHARM_2238_20140916092941